These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15688386)

  • 1. Simultaneous targeting of IL2 and IL12 to Hodgkin's lymphoma cells enhances activation of resting NK cells and tumor cell lysis.
    Hombach A; Heuser C; Abken H
    Int J Cancer; 2005 Jun; 115(2):241-7. PubMed ID: 15688386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CD30-scFv-Fc-IL-2 antibody-cytokine fusion protein that induces resting NK cells to highly efficient cytolysis of Hodgkin's lymphoma derived tumour cells.
    Heuser C; Guhlke S; Matthies A; Bender H; Barth S; Diehl V; Abken H; Hombach A
    Int J Cancer; 2004 Jun; 110(3):386-94. PubMed ID: 15095304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CD30-IL-12 antibody-cytokine fusion protein that induces IFN-gamma secretion of T cells and NK cell-mediated lysis of Hodgkin's lymphoma-derived tumor cells.
    Heuser C; Diehl V; Abken H; Hombach A
    Int J Cancer; 2003 Sep; 106(4):545-552. PubMed ID: 12845650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An IL12-IL2-antibody fusion protein targeting Hodgkin's lymphoma cells potentiates activation of NK and T cells for an anti-tumor attack.
    Jahn T; Zuther M; Friedrichs B; Heuser C; Guhlke S; Abken H; Hombach AA
    PLoS One; 2012; 7(9):e44482. PubMed ID: 23028547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30.
    Hombach A; Heuser C; Sircar R; Tillmann T; Diehl V; Pohl C; Abken H
    Cancer Res; 1998 Mar; 58(6):1116-9. PubMed ID: 9515791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of heterotransplanted Hodgkin's tumors in SCID mice by a combination of human NK or T cells and bispecific antibodies.
    Renner C; Pfreundschuh M
    J Hematother; 1995 Oct; 4(5):447-51. PubMed ID: 8581383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen.
    Hombach A; Heuser C; Sircar R; Tillmann T; Diehl V; Pohl C; Abken H
    J Immunother; 1999 Nov; 22(6):473-80. PubMed ID: 10570745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.
    Wahl AF; Klussman K; Thompson JD; Chen JH; Francisco LV; Risdon G; Chace DF; Siegall CB; Francisco JA
    Cancer Res; 2002 Jul; 62(13):3736-42. PubMed ID: 12097283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo.
    Hombach A; Jung W; Pohl C; Renner C; Sahin U; Schmits R; Wolf J; Kapp U; Diehl V; Pfreundschuh M
    Int J Cancer; 1993 Nov; 55(5):830-6. PubMed ID: 8244580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD30 is involved in inhibition of T-cell proliferation by Hodgkin's Reed-Sternberg cells.
    Su CC; Chiu HH; Chang CC; Chen JC; Hsu SM
    Cancer Res; 2004 Mar; 64(6):2148-52. PubMed ID: 15026356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells.
    Reusch U; Burkhardt C; Fucek I; Le Gall F; Le Gall M; Hoffmann K; Knackmuss SH; Kiprijanov S; Little M; Zhukovsky EA
    MAbs; 2014; 6(3):728-39. PubMed ID: 24670809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line.
    Klimka A; Barth S; Matthey B; Roovers RC; Lemke H; Hansen H; Arends JW; Diehl V; Hoogenboom HR; Engert A
    Br J Cancer; 1999 Jun; 80(8):1214-22. PubMed ID: 10376974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional humanization of an anti-CD30 Fab fragment for the immunotherapy of Hodgkin's lymphoma using an in vitro evolution approach.
    Schlapschy M; Gruber H; Gresch O; Schäfer C; Renner C; Pfreundschuh M; Skerra A
    Protein Eng Des Sel; 2004 Dec; 17(12):847-60. PubMed ID: 15708864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting macrophages in classical Hodgkin's lymphoma may seem rational, but is it safe?
    Dasanu CA
    J Oncol Pharm Pract; 2012 Mar; 18(1):104-8. PubMed ID: 21248172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-12 increases bispecific-antibody-mediated natural killer cell cytotoxicity against human tumors.
    Sahin U; Kraft-Bauer S; Ohnesorge S; Pfreundschuh M; Renner C
    Cancer Immunol Immunother; 1996 Jan; 42(1):9-14. PubMed ID: 8625370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of IL12 and IL2 on expression and function of cellular adhesion molecules on purified human natural killer cells.
    Rabinowich H; Herberman RB; Whiteside TL
    Cell Immunol; 1993 Dec; 152(2):481-98. PubMed ID: 7903063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.
    Hombach A; Sent D; Schneider C; Heuser C; Koch D; Pohl C; Seliger B; Abken H
    Cancer Res; 2001 Mar; 61(5):1976-82. PubMed ID: 11280755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic protein expression in non-Hodgkin's lymphomas and Hodgkin's disease.
    Kanavaros P; Vlychou M; Stefanaki K; Rontogianni D; Gaulard P; Pantelidaki E; Zois M; Darivianaki K; Georgoulias V; Boulland ML; Gorgoulis V; Kittas C
    Anticancer Res; 1999; 19(2A):1209-16. PubMed ID: 10368677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD30 expression utilization for the accuracy of classical Hodgkin's lymphoma staging.
    Flangea C; Potencz E; Mihăescu R; Anghel A; Gîju S; Motoc M; Dogaru C
    Rom J Morphol Embryol; 2006; 47(2):113-7. PubMed ID: 17106517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity.
    Peng LS; Penichet ML; Morrison SL
    J Immunol; 1999 Jul; 163(1):250-8. PubMed ID: 10384123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.